BOND-003
A cancer-killing virus instilled into the bladder produced complete responses in three quarters of patients whose BCG had failed, with almost no serious side effects.
CR at any time 75.2%; 24-month CR 41.8%; no grade 3+ treatment-related events. Published Lancet Oncology 2025. Rolling BLA submission under way in 2026 with completion expected in Q4 2026.
- 75.2 out of 100 people had no sign of cancer on scans or tests with Cretostimogene.
- 41.8 out of 100 people had no sign of cancer on scans or tests with Cretostimogene.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: BCG-unresponsive high-risk NMIBC with CIS: intravesical cretostimogene grenadenorepvec, single arm (cohort C). People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
110 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Complete response at any timeprimary | Cretostimogene | 110 | 75.2% | — | — | link |
| Complete response at 24 months | Cretostimogene | — | 41.8% | — | — | — |
Pages like this
not linked directly; found by shared links- CompanyCG Oncology
Shares Cretostimogene grenadenorepvec, Bladder & urothelial cancer.
- TrialSunRISe-1
- TrialQUILT 3.032
- ProductGemcitabine intravesical system (TAR-200)
- ProductNadofaragene firadenovec
- IdeaOncolytic viruses that make interleukin-12 only inside the tumour
Shares Cretostimogene grenadenorepvec, Oncolytic viruses, Bladder & urothelial cancer.
- TechnologyIntravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)
Shares Cretostimogene grenadenorepvec, BCG-unresponsive, Bladder & urothelial cancer.
- ProductNogapendekin alfa inbakicept